Fresh analysis reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional diet and exercise plans.
Research printed in a leading health publication demonstrates that while overweight people often shed about a fifth of their total mass while using the jabs, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using such treatments must be informed of the danger of rapid rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass in about one and a half years.
Comparing Treatments
The analysis, which examined dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through diet and exercise usually see a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Nutrition scientists believe the way of the injections accounts for the accelerated regain.
These medications copy a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
The NHS recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the therapy should be considered life-long.
This perspective is reinforced by drug manufacturers, who state that the results "underscore the long-term nature of obesity," akin to managing diseases like diabetes.
Patient Testimonies
People who have stopped the medication report a powerful return of hunger.
"I experienced a switch flipping and I was suddenly ravenous," said an individual.
This difficulty is worsened if patients have not adopted sustainable lifestyle or habit changes during treatment.
Significant Interest
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with demand remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated lifestyle management.
